|
TheraBond 3D is an advanced dressing designed to provide an antimicrobial barrier to prevent infections caused by contamination of burns, wounds, or surgical sites and to provide an optimal healing environment.
3D fabric technology describes the manufacturing process that produces a three dimensional (3D) nylon fabric that has a perforated contact surface, struts that connect the contact surface to a smooth outer surface. The three dimensional structure transfers fluids and exudates away from the wound and provides thermal insulation.
TheraBond 3D is manufactured based upon two technologies: an autocatalytic/electroless manufacturing process and 3D spacer fabric. The autocatalytic/electroless technology is used to bond silver to over 99% of the fibers in the fabric. When exposed to moisture in the wound, the dressing releases ionic silver a proven antimicrobial agent. The 3D spacer technology is designed to facilitate fluid and exudate transfer away from the wound.
When TheraBond 3D is exposed to moisture in a wound the fabric releases ionic silver. The effectiveness of ionic silver as an antimicrobial is well established. Laboratory data submitted to FDA proves that TheraBond 3D kills the pathogens commonly associated with wound infection including antibiotic resistant pathogens such as MRSA (methicillin-resistant Staph aureus) and VRE (vancomycin resistant Enterococci).
The dressing’s perforated contact surface takes up fluids and exudates from the surface of the wound. The fluid is actively transported by capillary action along the struts that connect the contact (wound) surface to the smooth outer surface of the dressing. Here the fluid and exudates are transferred into an absorbent outer dressing. Overall, the directional flow of this 3D delivery system is designed to maintain an ideal moist, but not wet, healing environment and to minimize the probability of the contact dressing becoming saturated.
The center core of the dressing is comprised of a network nylon struts that connect the contact surface to the outer surface of the dressing. Over 70%of the center core of the dressing is air. This acts as an insulator. Further, because fluid is transferred to the outer surface of the dressing, heat loss from evaporation is minimized. Minimizing heat loss reduces the patient’s metabolic energy requirement which has been shown to facilitate the healing process.
Waffle side down
–TheraBond 3D®’s antimicrobial action kills pathogens commonly associated with infection
–TheraBond 3D® provides an effective barrier against infection for fourteen (14) days.
NOTE: The results of these tests are summarized here (show the two tables in the product literature to your customer).
To show that TheraBond 3D® effectively kills pathogens commonly associated with infection we used a representative sample of Gram positive and Gram negative bacteria as well as spore forming and non spore forming fungi. TheraBond 3D was challenged with an infectious dose (greater than 105 [ten to the fifth] colony forming units) of each organism. In all cases there was at least a four log (104[ten to the fourth]) reduction of bacteria.
To show that TheraBond 3D® provides an effective barrier against pathogens passing through the dressing we used the same representative sample of pathogens. An infectious dose (greater than 105 colony forming units) of each organism was applied to the exterior (top of dressing) surface of TheraBond 3D. This was done over a period of fourteen (14) days. In all cases, there was no growth of the challenge organism on the dressing surface in contact with the growth media (bottom surface of the dressing). (If the customer wants more information, say that we will provide the protocols.)
Like any porous dressing, TheraBond 3D will adhere to wounds especially those rich in fibrin exudate. Sometimes adherence offers a clinical benefit, such as in partial thickness injuries and donor sites where adherence will provide comfort for the patient. When used in these clinical applications, TheraBond® should be left in place until the wound heals. Leaving the dressing in place prevents disruption of the re-epitheliazation and promotes patient comfort. When the wound is healed, TheraBond will release spontaneously. In applications where the clinician may want to observe the wound frequently, adherence would interfere with the clinical objectives. In these cases, a non-adherent dressing, such as Meplitel, should be applied as a contact layer.
If there is a foul odor but no other symptoms of infection such as fever or malaise, it is highly unlikely that the wound has become infected. The odor is a result of denatured proteins (------) that accumulate as part of the healing process. If the odor is intolerable, the dressing should be changed.
If there is a sufficient amount of exudate associated with the patients burn, there is no need to pre-moisten the TheraBond 3D. The fluid in the exudate will be sufficient to activate the dressing. In fact, the insatiable loss is sufficient to activate the dressing.
|
